ASC22 Market Size, Forecast, and Emerging Insight - 2032

ASC22 Market Size, Forecast, and Emerging Insight − 2032

“ASC22 Market Size, Forecast, and Emerging Insight − 2032” report provides comprehensive insights about ASC22 for chronic hepatitis B in the seven major markets and China. A detailed picture of the ASC22 for chronic hepatitis B in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China for the study period 2019 –2032 is provided in this report along with a detailed description of the ASC22 for chronic hepatitis B. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ASC22 market forecast analysis for chronic hepatitis B in the 7MM and China, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic hepatitis B.

Drug Summary

ASC22, also known as envafolimab, is a first-in-class, subcutaneously administered PD-L1 antibody for chronic hepatitis B (CHB) functional cure. It has the advantages of SC injection and good stability at room temperature. These would be of great value to improve patient’s compliance and quality of life and to help realize the goal of long-term management of chronic diseases such as chronic hepatitis B. Ascletis Pharma retains the global and exclusive rights to develop and commercialize ASC22 on viral indications.

Currently, the drug is being evaluated in a Phase II (NCT04465890) trial to evaluate the safety and efficacy of ASC22 in treating CHB after single and multiple drug administration. Interim results from the China Phase IIb clinical trial showed 1 mg/kg of ASC22 plus NAs for 24-week treatment were well-tolerated in CHB patients. 42.9% of patients with baseline HBsAg ≤100 IU/mL obtained sustained HBsAg loss, which indicates the potential of functional cure.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the ASC22 description, mechanism of action, dosage and administration, research and development activities in chronic hepatitis B.
• Elaborated details on ASC22 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ASC22 research and development activities in chronic hepatitis B across the United States, Europe, Japan, and China.
• The report also covers the patents information with expiry timeline around ASC22.
• The report contains forecasted sales of ASC22 for chronic hepatitis B till 2032.
• Comprehensive coverage of the late-stage emerging therapies for chronic hepatitis B.
• The report also features the SWOT analysis with analyst views for ASC22 in chronic hepatitis B.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ASC22 Analytical Perspective by DelveInsight

• In-depth ASC22 Market Assessment

This report provides a detailed market assessment of ASC22 for chronic hepatitis B in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China. This segment of the report provides forecasted sales data from 2027 to 2032.

• ASC22 Clinical Assessment

The report provides the clinical trials information of ASC22 for chronic hepatitis B covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for chronic hepatitis B is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ASC22 dominance.
• Other emerging products for chronic hepatitis B are expected to give tough market competition to ASC22 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ASC22 in chronic hepatitis B.
• Our in-depth analysis of the forecasted sales data of ASC22 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ASC22 in chronic hepatitis B.

Key Questions

• What is the product type, route of administration and mechanism of action of ASC22?
• What is the clinical trial status of the study related to ASC22 in chronic hepatitis B and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ASC22 development?
• What are the key designations that have been granted to ASC22 for chronic hepatitis B?
• What is the forecasted market scenario of ASC22 for chronic hepatitis B?
• What are the forecasted sales of ASC22 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China?
• What are the other emerging products available and how are these giving competition to ASC22 for chronic hepatitis B?
• Which are the late-stage emerging therapies under development for the treatment of chronic hepatitis B?